Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3224-3229

  Cai, Zhen Wei ^a   Wei, Donna ^a   Schroeder, Gretchen M ^a   Cornelius, Lyndon A M ^a   Kim, Kyoung ^a   Chen, Xiao Tao ^a   Schmidt, Robert J ^a   Williams, David K ^a   Tokarski, John S ^a   An, Yongmi ^a   Sack, John S ^a   Manne, Veeraswamy ^a   Kamath, Amrita ^a   Zhang, Yueping ^a   Marathe, Punit ^a   Hunt, John T ^a   Lombardo, Louis J ^a   Fargnoli, Joseph ^a   Borzilleri, Robert M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Met; Protein kinase inhibitors; Receptor tyrosine kinase

Indexed keywords

AMINOPYRIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLOPYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMINOPYRIDINES; ANIMALS; HUMANS; MICE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLES; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 44149124282     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.047     Document Type: Article

References (28)

1. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., and Salgia R. Cytokine & Growth Factor Rev. 13 (2002) 41
2. Birchmeier C., and Gherardi E. Trends Cell Biol. 8 (1998) 404
3. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K., and Nakamura T. Crit. Rev. Oncol. Hematol. 53 (2005) 35
4. Stewart F. Rev. Reprod. 1 (1996) 144
5. Huh C.-G., Factor V.M., Sanchez A., Uchida K., Conner E.A., and Thorgeirsson S.S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4477
6. Jeffers M., Rong S., and Vande Woude G.F. Mol. Cell. Biol. 16 (1996) 1115
7. Matsumoto K., Date K., Shimura H., and Nakamura T. Jpn. J. Cancer Res. 87 (1996) 702
8. Edakuni G., Sasatomi E., Satoh T., Tokunaga O., and Miyazaki K. Pathol. Int. 51 (2001) 172
9. DiRenzo M.F., Olivero M., Katsaros D., Crepaldi T., Gaglia P., Zola P., Sismondi P., and Comoglio P.M. Int. J. Cancer 58 (1994) 658
10. DiRenzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S., Plebani M., Gespach C., and Comoglio P.M. Clin. Cancer Res. 1 (1995) 147
11. For more information regarding the HGF/Met signaling pathway, see http://www.vai.org/met/.
12. Peruzzi B., and Bottaro D.P. Clin. Cancer Res. 12 (2006) 3657
13. Dussault I., Kaplan-Lefko P., Jun T., Coxon A., and Burgess T.L. Drugs Future 31 (2006) 819
14. Abidoye O., Murukurthy N., and Salgia R. Rev. Recent Clin. Trials 2 (2007) 143
15. Cui J.J. Expert Opin. Ther. Patents 17 (2007) 1035
16. Wang X., Le P., Liang C., Chan J., Kiewlich D., Miller T., Harris D., Sun L., Rice A., Vasile S., Black R.A., Howlett A.R., Patel N., McMahon G., and Lipson K.E. Mol. Cancer Ther. 2 (2003) 1085
17. Sattler M., Pride Y.B., Ma P., Gramlich J.L., Chu S.C., Quinnan L.A., Shirazian S., Liang C., Podar K., Christensen J.M., and Salgia R. Cancer Res. 63 (2003) 5462
18. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.J., Cherrington J.M., and Mendel D.B. Cancer Res. 63 (2003) 7345
19. Hov H., Holt R.U., Ro T.B., Fagerli U.-M., Hjorth-Hansen H., Baykov V., Christensen J.G., Waage A., Sundan A., and Borset M. Clin. Cancer Res. 10 (2004) 6686
20. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.-P., Nambu M.D., Los G., Bender S.L., Mroczkowski B., and Christensen J.G. Cancer Res. 67 (2007) 4408
21. Schroeder G.M., Chen X.-T., Williams D.K., Nirschl D., Cai Z.-W., Wei D., Tokarski J.S., An Y., Sack J., Chen Z., Huynh T., Vaccaro W., Poss M., Wautlet B., Gullo-Brown J., Kellar K., Manne V., Hunt J.T., Wong T.W., Lombardo L.J., Fargnoli J., and Borzilleri R.M. Bioorg. Med. Chem. Lett. 18 (2007) 1945
22. Borzilleri, R. M.; Chen, Z.; Huynh, T. N.; Vaccaro, W.; Chen, X.-T.; Kim, K. S. PCT Int. Patent Appl. WO 2006/004636, 2006.
23. Borzilleri, R. M.; Cornelius, L. A. M.; Schmidt, R. J.; Schroeder, G. M.; Kim, K. S. U.S. Patent Appl. 2005/0245530, 2005.
24. Feuerstein M., Berthiol F., Doucet H., and Santelli M. Synthesis (2004) 1281
25. Rodriguez A.L., Koradin C., Dohle W., and Knochel P. Angew. Chem. Int. Ed. 39 (2000) 2488
26. +: found: 399.1258, calcd: 399.1269.
27. For experimental details see:. Borzilleri R.M., Zheng X., Qian L., Ellis C., Cai Z.-W., Wautlet B.S., Mortillo S., Jeyaseelan R., Kukral D.W., Fura A., Kamath A., Vyas V., Tokarski J.S., Barrish J.C., Hunt J.T., Lombardo L.J., Fargnoli J., and Bhide R.S. J. Med. Chem. 48 (2005) 3991
28. For a detailed definition for %TGI, see Ref. 14. Antitumor activity of drug is defined as a %TGI > 50%.